Due to the rising number of lung cancer patients, the market for lung cancer therapies is expected to grow rapidly. The need for therapy and diagnostics for lung cancer in its advanced stages is still quite great. The growing senior population, shifting consumer lifestyles, and rising tobacco use, including passive smoking, are likely to be the market's major drivers. The market for lung cancer medicines is also thought to be significantly influenced by other variables, such as the focused and innovative delivery of pharmaceuticals to the lung and the growing acceptability of individualized treatments.
Market Size and Key Findings
The Global Lung Cancer Therapeutics size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.
Global Lung Cancer Therapeutics Size (In USD Bn)
(2021-2030F)
Market Dynamics
Market Growth Drivers Analysis
The growing elderly population, changing lifestyles, and rising tobacco use including passive smoking are the likely drivers for the worldwide lung cancer treatment market. The market for lung cancer medicines is also thought to be significantly influenced by other variables, such as the focused and innovative delivery of pharmaceuticals to the lung and the growing acceptability of individualized treatments.
Market Restraints
The main factors anticipated impeding the growth of the total lung cancer therapeutic market are the few available alternatives for therapy, the wide availability of generic versions of necessary medications, and the enormous unmet demand for diagnostics. Additionally, chemotherapy and radiation treatments both present significant risks for side effects. The key market participants must therefore concentrate their efforts on developing safer treatments and cutting-edge therapies.
Competitive Landscape
Key Players
The prominent players operating in this market include Pfizer Inc. (US), Merck & Co. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Boehringer Ingelheim (Germany), Allergan Inc. (Ireland), Bristol-Myers Squibb (US) and Eli Lilly and Company (US)
TABLE OF CONTENT
1. Report Description of the Global Lung Cancer Therapeutics
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. Global Lung Cancer Therapeutics Executive Summary
2.1 Global Lung Cancer Therapeutics – Industry Snapshot & key buying criteria, 2021-2030
2.2 Market Size, Growth Prospects, and Key findings
3. Market Dynamics of Global Lung Cancer Therapeutics
3.1 Market Growth Drivers Analysis
3.2 Market Restrains Analysis
4. Global Lung Cancer Therapeutics Segmentation
4.1 By Type
4.1.1 Small Cell Lung Cancer
4.1.2 Non-small Cell Lung Cancer
4.1.3 Lung Carcinoid Tumor
4.2 By Therapy
4.2.1 Radiation Therapy
4.2.2 Targeted Therapy
4.2.3 Immunotherapy
4.2.4 Chemotherapy
4.2.5 Others
4.3 By Type of Molecule
4.3.1 Small Molecules
4.3.2 Biologics
4.4 By Drug Class
4.4.1 Alkylating Agents
4.4.2 Antimetabolites
4.4.3 Multikinase Inhibitors
4.4.4 Mitotic Inhibitors
4.4.5 EGFR Inhibitors
4.4.6 Others
4.5 By Distribution Channel
4.5.1 Hospital Pharmacies
4.5.2 Retail Pharmacies
4.5.3 Online Pharmacies
5. Global Lung Cancer Therapeutics Share
5.1 Market Analysis, Insights, and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
7. Key Company Profiles
7.1 Company 1
7.1.1 Overview
7.1.2 Financial Performance
7.1.3 Product & Services
7.1.4 Strategic initiatives
7.2 Company 2
7.2.1 Overview
7.2.2 Financial Performance
7.2.3 Product & Services
7.2.4 Strategic initiatives
7.3 Company 3
7.3.1 Overview
7.3.2 Financial Performance
7.3.3 Product & Services
7.3.4 Strategic initiatives
7.4 Company 4
7.4.1 Overview
7.4.2 Financial Performance
7.4.3 Product & Services
7.4.4 Strategic initiatives
7.5 Company 5
7.5.1 Overview
7.5.2 Financial Performance
7.5.3 Product & Services
7.5.4 Strategic initiatives
8. Healthcare Policies and Regulatory Landscape
8.1 Healthcare Policies in Global
8.2 Regulatory Framework in Global
8.3 Pricing & Reimbursement Scenario in Global Lung Cancer Therapeutics
9. Factors Driving Future Growth
9.1 New Trends and Development Global Lung Cancer Therapeutics
9.2 Future Opportunities
10. Strategic Recommendations
Segmentation
Lung Cancer Therapeutics Segmentation
By Type (Revenue, USD Billion):
Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor
By Therapy (Revenue, USD Billion):
Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others
By Type of Molecule (Revenue, USD Billion):
Small Molecules
Biologics
By Drug Class (Revenue, USD Billion):
Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others
By Distribution Channel (Revenue, USD Billion):
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
